Researchers at CIC bioGUNE, led by Prof. José M. Mato and Dr. Óscar Millet, have developed a “metabolic aging clock” that uses a simple blood test to predict biological age and detect early signs of disease. Published in npj Metabolic Health and Disease, the tool leverages NMR metabolomics and machine learning to analyze small molecules in the blood, providing a more accurate measure of health than chronological age.

Developed with data from over 13,500 participants in the AKRIBEA cohort (Basque Country), the clock can reveal discrepancies between metabolic and chronological age, potentially signaling early disease. For example, prostate cancer patients showed a metabolic age nearly 5 years older than their actual age, while those with fatty liver disease had a difference of over 14 years. The system also detects subtype-specific disease patterns that traditional tests may miss.

Beyond aging, the platform can estimate 25+ clinical parameters, such as inflammation or kidney function, from the same blood sample, offering a non-invasive, personalized health assessment. The team aims to further validate the tool for broader use in healthcare, supporting early detection, risk stratification, and healthier aging.

A first-in-human Phase 1 study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in patients with relapsed small cell lung cancer (SCLC). 

The results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

 Zidesamtinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing, demonstrated clinically meaningful activity and durability in patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who had progressed on prior TKI therapy. 

Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ALK+ NSCLC, according to results from the Phase 3 E4512 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC). These findings were presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.